Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management|
- number of recurrent pterygia with postoperative bevacizumab [ Time Frame: 6 months ] [ Designated as safety issue: No ]The number of recurrent pterygia with patients who received bevacizumab after pterygium excision was compared to the number of recurrences in those patients who only had pterygium excision.
|Study Start Date:||April 2011|
|Study Completion Date:||April 2012|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
|Placebo Comparator: Pterygium Excision Alone|
|Experimental: Pterygium Excision with Bevacizumab Injection||Drug: Bevacizumab|
This is a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in size and without any previous ocular surgery will be included. Outcome measures will include best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening complications at two weeks, two months, and six months postoperatively.
|United States, California|
|Arrowhead Regional Medical Center|
|Colton, California, United States, 92624|
|Principal Investigator:||Keith Tokuhara, MD||Arrowhead Regional Medical Center|